Bibliography
- Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 1960;53:739-45
- Nilsson IM, Andersson L, Bjorkman SE. Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience. Acta Med Scand Suppl 1966;448:1-46
- Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007;120:654-8
- Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99:194-6
- Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999;353:1066-7
- Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005;115:864-9
- Monnier N, Ponard D, Duponchel C, et al. Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma. Mol Immunol 2006;43:2161-8
- Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C′1- esterase. Am J Med 1963;35:37-44
- Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962;33:330-41
- Pickering RJ, Good RA, Kelly JR, Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969;1:326-30
- Marasini B, Cicardi M, Martignoni GC, Agostoni A. Treatment of hereditary angioedema. Klin Wochenschr 1978;56:819-23
- Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 1980;44:299-301
- Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980;302:542-6
- Bergamaschini L, Cicardi M, Tucci A, et al. C1 INH concentrate in the therapy of hereditary angioedema. Allergy 1983;38:81-4
- Logan RA, Greaves MW. Hereditary angio-oedema: treatment with C1 esterase inhibitor concentrate. J R Soc Med 1984;77:1046-8
- Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001;161:714-8
- Kirschfink M, Mollnes TE. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2001;2:1073-83
- Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005;45:1774-84
- Maves KK, Weiler JM. Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate. Ann Allergy 1994;73:435-8
- Leimgruber A, Jaques WA, Spaeth PJ. Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol 1993;101:107-12
- Mohr M, Pollok-Kopp B, Gotze O, Burchardi H. The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema. Anaesthesist 1996;45:626-30
- Lehmann A, Lang J, Boldt J, Saggau W. Successful off-pump coronary artery bypass graft surgery in a patient with hereditary angioedema. J Cardiothorac Vasc Anesth 2002;16:473-6
- Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989;83:677-82
- De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apheresis Sci 2003;29:247-54
- Altman AD, Mclaughlin J, Schellenberg R, et al. Hereditary angioedema managed with low-dose danazol and C1 esterase inhibitor concentrate: a case report. J Obstet Gynaecol Can 2006;28:27-31
- Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334:1630-4
- Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998;38:540-9
- Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003;29:221-7
- Bergamaschini L, Cicardi M. Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol Immunol 2003;40:155-8
- Varga L, Szeplaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naive patients. Mol Immunol 2007;44:1454-60
- Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003;9:24-37
- Zuraw BL, Schaefer O, Grant JA, et al. Results of a randomized double-blind placebo controlled study of nanofiltered C1-inhibitor for the treatment of HAE attacks. American College of Allergy, Asthma & Immunology. Dallas, TX, USA; November 2007
- CSL Behring reaches primary endpoint in clinical study of C1-INH for treatment of hereditary angioedema. CSL Behring press release. 26 Nov 2007. Available from: http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1195505474707/prdetail.htm
- Koles K, Van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004;14:51-64
- Van Doorn MB, Burggraaf J, Van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005;116:876-83
- Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007;47:1028-32
- Schapira M, Silver LD, Scott CF, et al. Prekallikrein activation and high- molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983;308:1050-4
- Zuraw BL, Curd JG. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. JCI 1986;78:567-75
- Curd JG, Prograis L Jr, Cochrane CG. Detection of active kallikein in induced blister fluids of hereditary angioedema patients. J Exp Med 1980;152:742-7
- Curd JG, Yelvington M, Burridge N, et al. Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 1983;19:1365-5
- Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol 1983;72:54-60
- Davis AE III. The pathogenesis of hereditary angioedema. Transfus Apheresis Sci 2003;29:195-203
- Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apheresis Sci 2003;29:255-8
- Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:1057-63
- Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007;120:416-22
- Lumry W, Ritchie B, Beck T, Morrison J. Interim results of EDEMA2, a multicenter, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. American Academy of Allergy Asthma and Immunology, San Diego, CA, USA; March 2006
- Levy R, Mcneil D, Li H, et al. Results of a phase 3 double-blind, placebo-controlled trial, EDEMA3: a study of subcutaneous DX-88 (Ecallantide) in patients with hereditary angioedema. American College of Allergy Asthma and Immunology. Dallas, TX, USA; November 2007
- Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006;117:476-7
- Beck TR, Baird LG. Reply: anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006;117:477
- Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73
- Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497-503
- Bas M, Bier H, Greve J, et al. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 2006;61:1490-2
- Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl.):S51-131
- Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007;120:941-7
- Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007;21:101-17
- Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117:904-8
- Available from: www.jerini.com with permission